[French scale validation of the Infant Behavior Questionnaire three months after birth]. / Validation en langue française de l'instrument Infant Behavior Questionnaire (IBQ) à trois mois de vie de l'enfant.

Breastfeeding is recognize to be the perfect food of mother and child's health. The child's temperament is one of the factors that may explain pursuing the breastfeeding. Few instruments are available in French to measure this factor. The objective of the study is to present and validate the French translation of the scale "Infant Behavior Questionnaire" (IBQ). The sample consists of 193 primaparous or multiparous women who gave birth in a maternity in Paris. The child's temperament questionnaire was sent by mail three months after the birth. The same questionnaire was sent to a sub-sample of 30 women 15 days later. Analyses were conducted to assess the temporal stability, internal consistency, construct validity and predictive. The different results tend to show a compliant validity to the french scale version. This first IBQ French-language validation is worth pursuing in order to confirm the scale factor structure and participate to studies supporting mothers in their breastfeeding project.

An original administration of ifosfamide given once every other week: a clinical and pharmacological study.

Ifosfamide (IFOS) is a bifunctional alkylator with a wide spectrum of activity in solid tumors and has an autoinductive liver metabolism through P450 cytochromes. Autoinduction might permit a better therapeutic index for combination therapy. A phase I trial was investigated with interpatient dose escalation of a single dose of IFOS given every 2 weeks in advanced solid tumor patients. IFOS, its dechloroethylated and active 4-hydroxy metabolites, were measured at cycles 1 and 2 at the end of infusion, 2 and 5 h later, using gas chromatography. IFOS elimination was considered as following monocompartimental model kinetics. The results of 20 patients from January 2004 to June 2006 were included. The median of previous chemotherapies was 2 (0-5). The primary tumor was most often ovarian (5), peritoneal (3), sarcoma (2), melanoma (2) or miscellaneous (8). Ten patients received 2.5 g/m2 and the other 10 patients received 3 g/m2. A total of 79 cycles were evaluable for toxicity. The median number of cycles was 4 (1-8). No grade 3-4 toxicity, no alopecia at first dose level and no toxicity-related fatal events were noted. One objective response was noted in a pancreatic cancer patient and one sustained CA125 decline in a heavily pretreated ovarian cancer patient. A slight (7-10%) but reproducible decrease of areas under the curve was detectable at cycle 2, at both dose levels, related to autoinductive metabolism. Intraindividual variations (large SD) were noticed for each pharmacokinetic parameter. A patient-dependent autoinduction of IFOS metabolism was detected rather than a slight nondose-dependent autoinduction. The toxicity profile allows the development of bi-weekly IFOS-based combination therapies.